AI-designed 'universal vaccine' passes first human clinical trial, could prevent future pandemics

A vaccine created using artificial intelligence that could potentially provide broader protection against multiple coronaviruses and help prepare for future outbreaks has passed its first human clinical trial.

Researchers from the Universities of Cambridge and Southampton developed a "universal vaccine" designed to protect against multiple Sarbeco coronaviruses, which the university explained in a news release is "the large group of viruses that occur in nature including SARS-CoV-2, which caused the COVID pandemic."

CLICK HERE FOR MORE LIFESTYLE STORIES

Traditional vaccines must constantly be updated as viruses mutate, and the process is "like a dog chasing its tail," said University of Southampton professor Saul Faust, the trial’s chief investigator.

"Viruses like Influenza, Coronaviruses and the Ebola group are evolving continuously, and by the time vaccines are rolled out, they may be poorly matched – the current ‘reactive’ vaccine system struggles to keep pace," Faust said.

An antigen is the active ingredient in a vaccine meant to trigger an immune-system response and fight off infection. According to the release, the university scientists logged all the available genetic sequence data for Sarbeco coronaviruses and used AI used to design a "super-antigen" that contains the antigen features "common to this whole group of viruses – including ones that haven’t emerged yet."

The trial of the vaccine proved safe and triggered an immune response in 39 healthy volunteers, marking "the first time that a vaccine whose active component was designed entirely by computer simulations has been tested in humans," the release said.

CLICK HERE TO SIGN UP FOR OUR LIFESTYLE NEWSLETTER

The trial vaccine was administered through a micro-fluid jet that delivers the immunization through the skin using a tiny, high-pressure stream of liquid and does not require a needle. The researchers said this method could make it "faster and easier to carry out in large numbers of people."

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

"This new class of universal vaccines are future-proofed," Faust said. "They not only protect against many variants simultaneously, but potentially against related viruses that haven’t yet emerged and spilt over to humans. If we can develop and clinically advance this new class of vaccines before a virus outbreak begins, millions of lives could be saved, lockdowns avoided and the economy preserved."

Some experts have raised broad concerns about using AI in medicine, primarily when it comes to making clinical decisions, not developing vaccines. Certain groups of people may be underrepresented in the data AI relies on, resulting in biased outcomes, some said.

AI also sometimes produces erroneous information, called "hallucinations," and determining who is liable for medical failings in such situations is a complex matter.

Others have expressed concern over patient privacy, as well as the need for human judgement that takes into account the scope of a patient’s health history, rather than a single dataset.

The universal-vaccine researchers said that a larger trial involving "a wider and more diverse population" is needed. They published their findings in Journal of Infection.